TW261533B - - Google Patents

Info

Publication number
TW261533B
TW261533B TW082105589A TW82105589A TW261533B TW 261533 B TW261533 B TW 261533B TW 082105589 A TW082105589 A TW 082105589A TW 82105589 A TW82105589 A TW 82105589A TW 261533 B TW261533 B TW 261533B
Authority
TW
Taiwan
Prior art keywords
ych3
integer
ych
thrombocytopenia
remedy
Prior art date
Application number
TW082105589A
Other languages
English (en)
Chinese (zh)
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of TW261533B publication Critical patent/TW261533B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW082105589A 1992-07-16 1993-07-13 TW261533B (Direct)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21201592 1992-07-16
JP8521993 1993-03-19

Publications (1)

Publication Number Publication Date
TW261533B true TW261533B (Direct) 1995-11-01

Family

ID=26426239

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082105589A TW261533B (Direct) 1992-07-16 1993-07-13

Country Status (12)

Country Link
US (3) US5767092A (Direct)
EP (1) EP0650732B1 (Direct)
JP (1) JP3088461B2 (Direct)
KR (1) KR100277621B1 (Direct)
CN (1) CN1084623C (Direct)
AT (1) ATE200224T1 (Direct)
AU (1) AU684466B2 (Direct)
CA (1) CA2140013C (Direct)
DE (1) DE69330096T2 (Direct)
FI (1) FI950166A7 (Direct)
TW (1) TW261533B (Direct)
WO (1) WO1994002168A1 (Direct)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5849716A (en) * 1992-10-22 1998-12-15 Kirin Beer Kabushiki Kaisha Sphingoglycolipids, their preparation, and therapeutic methods of use
DE69416306T2 (de) * 1993-04-15 1999-06-17 Kirin Beer K.K., Tokio/Tokyo Sphingoglycolipid und verwendung davon
US6026815A (en) * 1996-10-10 2000-02-22 Gholam A. Peyman Radiopaque liquid as radiation blocking agent
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
WO1998034623A1 (en) * 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
AU2001268564A1 (en) * 2000-06-22 2002-01-02 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
AU2002327097B2 (en) * 2001-08-16 2007-05-24 Japan As Represented By President Of National Centre Of Neurology And Psychiatry Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
US8443383B2 (en) * 2002-05-03 2013-05-14 Time Warner Cable Enterprises Llc Use of messages in program signal streams by set-top terminals
AU2003266530A1 (en) * 2002-09-20 2004-04-08 Kirin Beer Kabushiki Kaisha HEPATITIS C VIRUS INHIBITOR COMPRISING Alpha-GLYCOSYLCERAMIDE AS THE ACTIVE INGREDIENT
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
CA2519568C (en) * 2003-03-20 2012-01-03 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
US7309015B2 (en) * 2004-07-14 2007-12-18 Scanbuy, Inc. Mobile device gateway providing access to instant information
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
AU2005294150B2 (en) 2004-10-07 2011-06-16 Coimmune, Inc. Mature dendritic cell compositions and methods for culturing same
US7923013B2 (en) * 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
DK1848813T3 (da) 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
WO2006096500A2 (en) * 2005-03-04 2006-09-14 The Regents Of The University Of California Highly efficient synthesis of alpha-o-galactosyl ceramides
JPWO2007004705A1 (ja) * 2005-07-01 2009-01-29 国立精神・神経センター総長 糖脂質誘導体及びそれを有効成分とする治療剤
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
ES2397975T3 (es) * 2006-04-07 2013-03-12 The Scrips Research Institute Galactosilceramida modificada para el tratamiento de enfermedades cancerosas
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
US8263576B2 (en) * 2006-08-15 2012-09-11 Mayo Foundation For Medical Education And Research Non-natural sphingolipid analogs and uses thereof
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
CN102066394B (zh) * 2007-10-12 2015-04-01 路易吉·潘扎 用作免疫佐剂的糖脂的类似物
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
JP5813953B2 (ja) * 2007-12-05 2015-11-17 アビバックス 抗原に対する免疫応答を増強する組成物および方法
BRPI0914069A2 (pt) * 2008-10-08 2016-09-27 Vincent Serra composição de vacina para uso contra o influenza
ES2620478T3 (es) 2009-02-16 2017-06-28 Cerenis Therapeutics Holding Sa Miméticos de la apolipoproteína A-I
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
ES2675582T3 (es) 2010-12-02 2018-07-11 Riken Inmunoterapia utilizando células alo-NKT, células para inmunoterapia en las que la cadena alfa del gen del receptor de las células T (TCR) ha sido redistribuida a V alfa-J alfa uniforme, y banco de células NKT derivadas de dichas células
WO2013119857A1 (en) 2012-02-07 2013-08-15 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
CA2882553A1 (en) 2012-08-22 2013-08-22 Regimmune Corporation Preparation for preventing or treating type i diabetes
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
CN105120877A (zh) 2012-11-05 2015-12-02 株式会社雷吉姆恩 免疫耐受诱导物
US10151745B2 (en) 2012-11-21 2018-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for determining the risk of acute graft versus host disease
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
JPWO2022118913A1 (Direct) 2020-12-04 2022-06-09

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622666A (en) * 1968-03-04 1971-11-23 Stanley Drug Products Inc Methods for treating bacterial infections with phrenosin
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4806466A (en) * 1981-10-29 1989-02-21 The Regents Of The University Of California Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
JPS6157594A (ja) * 1984-08-30 1986-03-24 Suntory Ltd ガラクトスフインゴ脂質及びその製造法
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
DD261165A5 (de) * 1985-08-13 1988-10-19 Solco Basel Ag,Ch Neues verfahren zur herstellung von sphingosinderivaten
JPH07116209B2 (ja) * 1986-04-11 1995-12-13 メクト株式会社 シアロシルセラミド類及びその製造方法
US4990603A (en) * 1986-07-04 1991-02-05 Mect Corporation Sialic acid derivatives and process therefor
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JP2588729B2 (ja) * 1987-10-05 1997-03-12 塩野義製薬株式会社 スフィンゴシン誘導体
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JP2631532B2 (ja) * 1988-10-14 1997-07-16 富士写真フイルム株式会社 熱転写受像材料
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
IT1235162B (it) * 1988-12-02 1992-06-22 Fidia Farmaceutici Derivati di lisosfingolipidi
US5028715A (en) * 1989-02-06 1991-07-02 Southwest Research Institute Radioprotective agents and their method of manufacture
US5210073A (en) * 1989-09-29 1993-05-11 Ajinomoto Co., Inc. Method for treating cancer therapy radiation damage or arteriosclerosis using human adf
JP3068910B2 (ja) * 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
JPH06145189A (ja) * 1991-01-23 1994-05-24 Kitasato Inst:The スフィンゴ糖脂質
JP3034650B2 (ja) * 1991-06-19 2000-04-17 株式会社ジーシー 歯質用接着剤
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
DE69416306T2 (de) * 1993-04-15 1999-06-17 Kirin Beer K.K., Tokio/Tokyo Sphingoglycolipid und verwendung davon

Also Published As

Publication number Publication date
HK1009937A1 (en) 1999-09-17
DE69330096T2 (de) 2001-10-18
CN1084623C (zh) 2002-05-15
FI950166A7 (fi) 1995-01-31
FI950166A0 (fi) 1995-01-13
EP0650732A4 (en) 1998-04-01
CA2140013C (en) 2002-08-27
WO1994002168A1 (fr) 1994-02-03
KR100277621B1 (ko) 2001-02-01
AU4583593A (en) 1994-02-14
KR950702431A (ko) 1995-07-29
US5767092A (en) 1998-06-16
CN1088093A (zh) 1994-06-22
US6017892A (en) 2000-01-25
DE69330096D1 (de) 2001-05-10
CA2140013A1 (en) 1994-02-03
ATE200224T1 (de) 2001-04-15
AU684466B2 (en) 1997-12-18
JP3088461B2 (ja) 2000-09-18
EP0650732B1 (en) 2001-04-04
EP0650732A1 (en) 1995-05-03
US6071884A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
TW261533B (Direct)
NO941589D0 (Direct)
SG48939A1 (en) Azole compounds their production and use
AU9107491A (en) 1,4-benzothiazepine derivative
EP0632031A4 (Direct)
CA1255684C (Direct)
GR3025293T3 (en) Spicamycin derivatives and the use thereof
ZA897022B (en) Antihypercholesterolemic 4,5-diaryl-2-substituted thioimidazoles
EP0760362A4 (en) NEW DIAMINOMETHYLIDES DERIVATIVES
HUT49887A (en) Process for producing new cefem compounds
CA2052020A1 (en) Pradimicin derivatives
TW218020B (en) A protective agent against irradiation damage
MY109672A (en) Azole compounds, their production and use